Journal of Virus Eradication

Aims & Scope

The Journal of Virus Eradication aims to provide a specialist, open-access forum to publish work in the rapidly developing field of virus eradication.

The Journal covers all human viruses, in the context of new therapeutic strategies, as well as societal eradication of viral infections with preventive interventions.

The Journal is aimed at the international community involved in the prevention and management of viral infections.

It provides an academic forum for the publication of original research into viral reservoirs, viral persistence and virus eradication and ultimately development of cures.

All submissions are peer reviewed by experts who work at major international centers of excellence.

The Journal not only publishes original research, but provides an opportunity for opinions, reviews, case studies and comments on the published literature.

It focusses on evidence-based medicine as the major thrust in the successful management of viral infections.

The Journal encompasses virological, immunological, epidemiological, modelling, pharmacological, pre-clinical and in vitro, as well as clinical, data including but not limited to drugs, immunotherapy and gene therapy.

It is an important source of information on the development of vaccine programs and preventative measures aimed at virus eradication.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Immunology and Microbiology and Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Immunology and Microbiology and Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 2,730.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?

  Citation: 204

  Authors: Victoria, Toby, Andrew

• The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries

  Citation: 113

  Authors: Andrew M., Sanjay, Bryony

• Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

  Citation: 106

  Authors: Andrew, Sophie L., Dzintars, Anton L.

• Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection

  Citation: 89

  Authors: Jintanat, Carlo P., Suteeraporn, Nicolas, Mark, Tassanee, Alexandra, Shelly J., Robin, Linda, Sasiwimol, Rapee, Sodsai, Serena, Victor, Irini, Nelson, Merlin, Praphan, Jerome H., Nittaya

• Are new antiretroviral treatments increasing the risks of clinical obesity?

  Citation: 86

  Authors: Andrew, Laura, Anton

• Establishment of latent HIV-1 reservoirs: what do we really know?

  Citation: 79

  Authors: Jef, Anne, Zeger

• HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?

  Citation: 76

  Authors: Deanna A., Nicolas

• How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP

  Citation: 74

  Authors: Victoria, Andrew, Sophie, Nneka, Anton

• Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam

  Citation: 72

  Authors: Suresh, Donn J., Le Truong, Duc Duong, Huu, Plui Broh, Tran Tri, Ngoc Bao Chau, Duc Anh, Bao Tram, Vu Tuyet Nga, Nhat Quang, Van Phuoc, D.uc Giang, Mario, Yanwu, Thi Thu, My Hanh, Thi Hoa, Xuan Chien, Gary

• Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India)

  Citation: 71

  Authors: Paulo R.S., Ives, Helyson L.B., Cíntia, Marilia, Paula, Eduardo M.